ProQR director granted 14,495 share options

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of options to buy 14,495 ordinary shares.

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of options to buy 14,495 ordinary shares. These share options have an exercise price of $1.42 per share and expire on June 1, 2036, functioning as equity-based compensation rather than an open-market trade.

According to the vesting terms, 25% of the options vest and become exercisable on June 2, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter, contingent on continuous service. After this grant, the filing shows 14,495 derivative securities held.

Insider Trade Summary

Grant/Award: 14,495 shares

Grant/Award 1 txn

Insider Hinsch Gylvin Lykke

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	14,495	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 14,495 contracts (Direct)

Footnotes (2)

1. F1. The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.
2. F2. 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Options granted: 14,495 share options Exercise price: $1.42 per share Expiration date: June 1, 2036 +3 more

6 metrics

Options granted 14,495 share options Grant to director Hinsch Gylvin Lykke

Exercise price $1.42 per share Strike price for option grant

Expiration date June 1, 2036 Option term end

Initial vesting 25% on June 2, 2027 First vesting tranche

Remaining vesting 75% in 12 quarterly installments Post-2027 vesting schedule

Derivative holdings after grant 14,495 derivative securities Total options held following transaction

Key Terms

Share Option (Right to Buy), exercise price, vest and become exercisable, expiration date

4 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.4200" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable"

expiration date financial

"expiration_date: "2036-06-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ProQR Therapeutics (PRQR) report for Hinsch Gylvin Lykke?

ProQR Therapeutics reported that director Hinsch Gylvin Lykke received 14,495 share options as equity compensation. These options give the right to buy ordinary shares at an exercise price of $1.42 per share and are not an open-market stock purchase or sale.

What are the key terms of the ProQR (PRQR) option grant to Hinsch Gylvin Lykke?

The grant covers 14,495 share options with an exercise price of $1.42 per share and an expiration date of June 1, 2036. The filing shows 14,495 derivative securities held following the transaction, indicating this award establishes the reported option position.

How do the ProQR (PRQR) options granted to Hinsch Gylvin Lykke vest over time?

Vesting occurs gradually. 25% of the options vest and become exercisable on June 2, 2027. The remaining 75% vest in 12 substantially equal quarterly installments after that date, provided Hinsch Gylvin Lykke continues serving ProQR throughout the vesting schedule.

Is the ProQR (PRQR) Form 4 transaction a stock purchase or sale?

No, the Form 4 reflects an option grant, not a direct stock purchase or sale. Hinsch Gylvin Lykke acquired 14,495 share options as compensation, with an exercise price of $1.42 per share, and no open-market buying or selling is reported in this filing.

When do the newly granted ProQR (PRQR) options for Hinsch Gylvin Lykke expire?

The options granted to Hinsch Gylvin Lykke expire on June 1, 2036. This long-dated expiration gives ample time after vesting dates for potential exercise, assuming the director maintains continuous service and chooses to exercise the options in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hinsch Gylvin Lykke

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$1.42(1)	06/02/2026		A		14,495		(2)	06/01/2036	Ordinary Shares	14,495	$0	14,495	D

Explanation of Responses:

1. The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.

2. 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)